Oric Pharmaceuticals
Liliana Soroceanu, MD PhD, currently serves as the Translational Medicine-Biomarker Lead and Senior Principal Scientist at ORIC Pharmaceuticals Inc., focusing on clinical biomarker development for precision oncology targets since November 2023. Previously, Liliana worked as the Director of Translational Medicine at Kinnate Biopharma Inc. from January to October 2023 and as a Senior Scientist at CPMC Research Institute from October 2015 to January 2023, where Liliana led a multi-disciplinary team in translational oncology, emphasizing target discovery and combinatorial therapies. Earlier experience includes roles as a Scientist at CPMC Research Institute (2007-2015), investigating the role of cytomegalovirus in cancer, and as a Postdoctoral Research Fellow at Genentech (2002-2007), contributing to the molecular classification of glioblastoma. Liliana holds a PhD in Neurobiology from the University of Alabama at Birmingham and an MD from Grigore T. Popa University of Medicine and Pharmacy Iași.
This person is not in any teams
Oric Pharmaceuticals
ORIC Pharmaceuticals is a privately held, clinical-stage oncology company focused on making cancer treatments more effective by addressing mechanisms of resistance. ORIC's lead asset, ORIC-101, is a potent and selective small-molecule antagonist of the glucocorticoid receptor. ORIC's pipeline targets other undisclosed mechanisms of oncology therapy resistance. ORIC's scientific founders are Drs. Charles Sawyers, MD, and Scott Lowe, PhD, who have strong records of discovering innovative treatments and targets in cancer. The company has assembled strong leadership and scientific teams and a board with extensive experience in drug development and financing. ORIC is funded by leading biotechnology investors, including The Column Group, Topspin Partners, OrbiMed Advisors, EcoR1 Capital, Fidelity Management & Research Company, Trinitas Capital, Foresite Capital, Taiho Ventures, Memorial Sloan Kettering, Kravis Investment Partners, NS Investment and City Hill Ventures. ORIC is headquartered in South San Francisco, California.